FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Capricor Gets FDA OK on Duchenne BLA Refiling

[ Price : $8.95]

Capricor Therapeutics reaches agreement with FDA on the design and role of its HOPE-3 trial as it works to resubmit its BLA for De...

Hansa Biopharmas Imlifidase Hits Primary Endpoint

[ Price : $8.95]

Hansa Biopharma says imlifidase met the primary endpoint in a pivotal Phase 3 study in kidney transplant patients.

FDA NextGen Submission Portal Guide

[ Price : $8.95]

FDA publishes a guide to its Electronic Submission Gateway NextGen Unified Submission Portal.

Public Confidence in FDA, Others Dropping: Survey

[ Price : $8.95]

The latest University of Pennsylvania Annenberg Public Policy Center survey documents a significant drop since last fall in the pe...

Lillys Inluriyo OKd for Breast Cancer

[ Price : $8.95]

FDA approves an Eli Lilly NDA for Inluriyo (imlunestrant, 200 mg tablets), an oral estrogen receptor antagonist for treating certa...

CBER Posts 13 FDA Form-483s

[ Price : $8.95]

CBER posts 13 Form FDA-483s under the Freedom of Information Acts provision on frequently requested records.

Biolinq Gets De Novo for Glucose Sensor

[ Price : $8.95]

FDA grants Biolinq a de novo authorization for its Shine system, said to be the first fully autonomous, needle-free glucose sensor...

Cellebration Refusing to Provide Records to FDA

[ Price : $8.95]

FDA warns San Juan, Puerto Rico-based Cellebration LLC that it is violating the Federal Food, Drug, and Cosmetic Act and agency re...

Acadias Phase 3 Trial of Intranasal Carbetocin Fails

[ Price : $8.95]

Acadia Pharmaceuticals says it will cease developing intranasal carbetocin after its Phase 3 COMPASS PWS trial of the drug for tre...

Regenerative Therapies Expedited Programs

[ Price : $8.95]

FDA publishes a draft guidance with recommendations for expedited development and review of regenerative medicine therapies for se...